PFIZER subsidiary, Upjohn Australia, is on track for a return to wholesale distribution from 24 Feb, after signing contracts with five Community Service Obligation (CSO) wholesalers.
Since announcing the decision to move away from the DHL-run Pfizer Direct platform in Dec (PD 18 Dec 2019), Upjohn has signed distribution deals with Symbion, Sigma Healthcare, API (Australian Pharmaceutical Industries), CH2 (Clifford Hallam Healthcare) and CHS (Central Healthcare Services).
Upjohn General Manager Australia and New Zealand, Gareth Richmond, said the repositioning of the distribution of Upjohn medicines with wholesalers is a commercial decision to ensure the business is in the best position for growth going forward.
"Upjohn's decision will ensure community and hospital pharmacies in Australia continue to have access to our portfolio of medicines, which is our utmost priority," he said.
While Upjohn products will only be distributed through CSO wholesalers from 24 Feb, other Pfizer originator, generic and biosimilar medications will continue to be supplied exclusively through the Pfizer Direct channel.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Feb 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Feb 20
